Deleted Tweets From Scott Gottlieb, R-D.C.

1/3 This year the #flu has been widespread, impacting millions of patients across the country, and leading to a new record number of flu-related hospitalizations, surpassing those in the 2014-2015 flu season

2/3 People want to know why the level of protection they expect from their annual flu vaccine is diminished. We share the concern and are working with our @CDCFlu colleagues to determine why this season’s vaccine is offering suboptimal protection for H3N2

3/3 #FDA is committed to collaborating with other health agencies to use the lessons that we are learn — and will continue to learn -- from this year’s #flu outbreak and our evaluation of the seasonal vaccine to prepare for next year

1/3 #FDA works with gov’t partners to select strains for the annual #flu vaccine. Flu vaccines are adapted yearly based on science-based predictions of strains most likely to hit U.S. next season. It’s based on imp data, research, expertise; but unfortuna

RT @FDAOncology: In 2017, @FDAOncology approved 17 new drug and biologic applications, 32 supplemental drug and biologic application… https://t.co/JCLpPEab2J

3/3 There are several potential reasons why we may be seeing less than optimal protection from this year's vaccine that are being investigated. We're actively working on elucidating the causes with colleagues at @CDCFlu and we'll communicate this week as

2/3 While yearly #flu vaccines will likely never provide 100% protection against the flu (we always see differences in strains from year to year) it appears this year’s vaccine is offering suboptimal protection for H3N2 - this most predominant strain the

RT @DepSecHargan: Great to be at the @AccessibleMeds annual conference talking about our work to lower #DrugPrices. https://t.co/8wd7HXArwc

1/2 #FDA plays an important role in protecting public health by working with partners to select strains for the annual #flu vaccine based on best scientific predictions of the strains most likely to hit next season.

2/2 The just announced March 1 meeting of the Vaccines & Related Biological Products Advisory Committee (VRBPAC) will use lessons learned this year to make recommendations on selection of strains to be included in flu vaccines for 2018-2019: https://t

RT @FDAOncology: March 15 #OCEListens18 Oncology Center of Excellence public listening session. Registration:… https://t.co/Hrb4lG5bUX

RT @NCIDirector: NEW online Cancer Trends Progress Report provides up-to-date measures of progress across the #cancer control contin… https://t.co/zne8I912qT

What is the difference between a biosimilar and an interchangeable product? Visit FDA’s website to find out. https://t.co/NpfezOhhS1 https://t.co/fCqba4wiN2

RT @FDA_Drug_Info: FDA requires that #generics meet the same high standards as brand-name drugs do. Get the facts this #HeartMonth.… https://t.co/T5CmmiJCjq

RT @FDA_ORA: FDA’s Special Agents/@TheJusticeDept: NY oncologist & spouse to pay $500K for submitting false Medicare claims for… https://t.co/n5yhAWtB56

FDA requires that #generics meet the same high standards as brand-name drugs do. Get the facts this #HeartMonth. https://t.co/YS5CBjK0DA https://t.co/8dAcfgOBPh

#FDA is grateful for the Administration’s continued support of its vital public health mission and the resources for initiatives that we believe will ultimately lead both to better health outcomes for American families and greater U.S. economic developmen

RT @FDAMedia: FDA request for funds to promote innovation, broaden patient access: https://t.co/R6wJwIWjQ8

My statement: FY19 budget req funds #FDA’s current programs at consistent levels/support core public health mission. It also includes addtl ~$400M to advance initiatives to further promote innovation/competition & advance health/safety of American fam

RT @FDA_Track: Statement from FDA Commissioner Scott Gottlieb, M.D., on Administration’s request for new FDA funding to promote in… https://t.co/CQOYzZp4ua

1/3 This year the #flu has been widespread, impacting millions of patients across the country, and leading to a new record number of flu-related hospitalizations, surpassing those in the 2014-2015 flu season

2/3 People want to know why the level of protection they expect from their annual flu vaccine is diminished. We share the concern and are working with our @CDCFlu colleagues to determine why this season’s vaccine is offering suboptimal protection for H3N2

3/3 #FDA is committed to collaborating with other health agencies to use the lessons that we are learn — and will continue to learn -- from this year’s #flu outbreak and our evaluation of the seasonal vaccine to prepare for next year

1/3 #FDA works with gov’t partners to select strains for the annual #flu vaccine. Flu vaccines are adapted yearly based on science-based predictions of strains most likely to hit U.S. next season. It’s based on imp data, research, expertise; but unfortuna

RT @FDAOncology: In 2017, @FDAOncology approved 17 new drug and biologic applications, 32 supplemental drug and biologic application… https://t.co/JCLpPEab2J

3/3 There are several potential reasons why we may be seeing less than optimal protection from this year's vaccine that are being investigated. We're actively working on elucidating the causes with colleagues at @CDCFlu and we'll communicate this week as

2/3 While yearly #flu vaccines will likely never provide 100% protection against the flu (we always see differences in strains from year to year) it appears this year’s vaccine is offering suboptimal protection for H3N2 - this most predominant strain the

RT @DepSecHargan: Great to be at the @AccessibleMeds annual conference talking about our work to lower #DrugPrices. https://t.co/8wd7HXArwc

1/2 #FDA plays an important role in protecting public health by working with partners to select strains for the annual #flu vaccine based on best scientific predictions of the strains most likely to hit next season.

2/2 The just announced March 1 meeting of the Vaccines & Related Biological Products Advisory Committee (VRBPAC) will use lessons learned this year to make recommendations on selection of strains to be included in flu vaccines for 2018-2019: https://t

RT @FDAOncology: March 15 #OCEListens18 Oncology Center of Excellence public listening session. Registration:… https://t.co/Hrb4lG5bUX

RT @NCIDirector: NEW online Cancer Trends Progress Report provides up-to-date measures of progress across the #cancer control contin… https://t.co/zne8I912qT

What is the difference between a biosimilar and an interchangeable product? Visit FDA’s website to find out. https://t.co/NpfezOhhS1 https://t.co/fCqba4wiN2

RT @FDA_Drug_Info: FDA requires that #generics meet the same high standards as brand-name drugs do. Get the facts this #HeartMonth.… https://t.co/T5CmmiJCjq

RT @FDA_ORA: FDA’s Special Agents/@TheJusticeDept: NY oncologist & spouse to pay $500K for submitting false Medicare claims for… https://t.co/n5yhAWtB56

FDA requires that #generics meet the same high standards as brand-name drugs do. Get the facts this #HeartMonth. https://t.co/YS5CBjK0DA https://t.co/8dAcfgOBPh

#FDA is grateful for the Administration’s continued support of its vital public health mission and the resources for initiatives that we believe will ultimately lead both to better health outcomes for American families and greater U.S. economic developmen

RT @FDAMedia: FDA request for funds to promote innovation, broaden patient access: https://t.co/R6wJwIWjQ8

My statement: FY19 budget req funds #FDA’s current programs at consistent levels/support core public health mission. It also includes addtl ~$400M to advance initiatives to further promote innovation/competition & advance health/safety of American fam

RT @FDA_Track: Statement from FDA Commissioner Scott Gottlieb, M.D., on Administration’s request for new FDA funding to promote in… https://t.co/CQOYzZp4ua